Clinical trials: Excess Abdominal Fat
Excess Abdominal Fat
UltraShape Power Device for Fat Reduction in Flanks
Prospective, baseline-controlled evaluation of the UltraShape Power device for non-invasive fat reduction in flanks.
- Trial name
- NCT03502473
- Testing
- UltraShape Power device
- Where
- Israel
- Volunteers
- healthy volunteers welcome
- Sponsor
- Syneron Medical
Excess Abdominal Fat
Clinical Study to Evaluate the Safety and Efficacy of the UltraShape Device for Non-Invasive Abdominal Fat Reduction
Prospective, blinded, one arm, baseline-controlled clinical study for the evaluation of the UltraShape treatment for non-invasive abdominal fat reduction. Study subjects will undergo UltraShape treatments on the abdominal area
- Trial name
- NCT02700152
- Testing
- UltraShape
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Syneron Medical
Lipodystrophy, HIV Infections
TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy
Assessing the Efficacy and Long-Term Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat Accumulation
- Trial name
- NCT00608023
- Testing
- Tesamorelin
- Where
- 47 sites in United States, Belgium and 4 more
- Volunteers
- 263 people
- Sponsor
- Theratechnologies
Excess Abdominal Fat
UltraShape Power for Abdominal Fat and Circumference Reduction
Prospective, one arm, baseline-controlled, clinical study for the evaluation of the UltraShape Power treatment using the U-Sculpt Power Transducer for non-invasive abdominal fat and circumference reduction.
- Trial name
- NCT02748928
- Testing
- UltraShape Power
- Where
- 8 sites in United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Syneron Medical
Diabetes Mellitus, Type 2, Insulin Resistance
Evaluation of Intra-Abdominal Fat Extraction Using HydraSolve T2D™ in Obese Subjects With Type 2 Diabetes
This study will investigate the safety and efficacy of the investigational use of the HydraSolve T2D™ System in improving blood glucose control and insulin resistance in patients with obesity (Class 1, BMI 30-39.9 kg/m2) and type…
- Trial name
- NCT03953963
- Testing
- HydraSolve T2D™
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Medality Medical
HIV Infections, Lipodystrophy
TH9507 in Patients With HIV-Associated Lipodystrophy
HIV lipodystrophy affects a significant proportion of patients treated with combination antiretroviral therapy (ART) and is characterized by excess visceral fat accumulation and loss of extremity and subcutaneous fat, in…
- Trial name
- NCT00123253
- Testing
- TH9507
- Where
- 42 sites in United States, Canada
- Volunteers
- 412 people
- Sponsor
- Theratechnologies